Day One Biopharmaceuticals, Inc. (DAWN) Q2 2023 Earnings Results

Day One Biopharma Misses on EPS — Stock Down 4.11%

The earnings report indicates that Day One Biopharma is still facing challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 4.11%, likely due to the lack of revenue information and forward guidance. Investors may be concerned about the company's future trajectory without clear financial targets.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.61	N/A	-0.99%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious approach regarding future performance. They emphasized the importance of their clinical pipeline but did not provide specific financial guidance.

Management did not provide specific guidance for future performance.

The company is focusing on its ongoing clinical trials and product development.

Day One Biopharma Misses on EPS — Stock Down 4.11%

Key numbers

Management commentary

Day One Biopharmaceuticals, Inc.

More earnings this week

Day One Biopharma Misses on EPS — Stock Down 4.11%

Key numbers

Management commentary